Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

被引:0
|
作者
Ivars, David [1 ]
Collado, Rosa [2 ]
Alguero, Carmen [1 ]
Carmen Tormos, M. [1 ]
Diaz, Laura [1 ]
Luis Garcia-Ghnenez, Jose [3 ]
Arrizabalaga, Beatriz [4 ]
Orero, Mayte [2 ]
Perez, Pedro [2 ]
Sanchez, Magdalena [2 ]
Angeles Ruiz, M. [5 ]
Yaguee, Nuria [5 ]
Sancho-Tello, Reyes [6 ]
Regadera, Ana [7 ]
Tormo, Mar [8 ]
Egea, Mercedes [2 ]
Vidal, Elena [2 ]
Enrique O'Connor, J. [1 ]
Saez, Guillermo T. [1 ]
Carbonell, Felix [2 ]
机构
[1] Univ Valencia, Valencia, Spain
[2] Hosp Gen Univ Valencia, Biomed Diag Ctr, Hematol Serv, Valencia, Spain
[3] Biomed Network Res Ctr Rare Dis, CIBERER, Valencia, Spain
[4] Hosp Cruces, Baracaldo, Spain
[5] Hosp Francesc de Borja, Valencia, Spain
[6] Hosp Arnau Vilanova, Hematol Serv, Valencia, Spain
[7] Hosp Gen Requena, Hematol Serv, Valencia, Spain
[8] Hosp Clin, Valencia, Spain
关键词
D O I
10.1182/blood.V120.21.4956.4956
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
4956
引用
收藏
页数:2
相关论文
共 50 条
  • [31] T cell mediated autologous cytotoxicity against hematopoietic precursor cells in low and intermediate-1 risk Myelodysplastic syndrome.
    Chamuleau, Martine E. D.
    Westers, Theresia M.
    van Dreunen, Linda
    Groenland, Judith
    Zevenbergen, Adri
    Eeltink, Corien
    Ossenkoppele, Gert J.
    de Loosdrecht, Arjan A. Van
    BLOOD, 2007, 110 (11) : 223B - 223B
  • [32] Low-risk myelodysplastic syndromes and iron overload
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 9 - 9
  • [33] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    CYTOTHERAPY, 2024, 26 (06) : S40 - S40
  • [34] IRON OVERLOAD AND TRANSIENT ELASTOGRAPHY IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Risum, M.
    Barfod, T.
    Raaschou-Jensen, K.
    LEUKEMIA RESEARCH, 2015, 39 : S58 - S59
  • [35] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Schnell, R.
    Lerchenmueller, C.
    Sauer, A.
    Severin, K.
    Germing, U.
    Steinmetz, H. T.
    ONKOLOGIE, 2012, 35 : 148 - 148
  • [36] Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy
    Leitch, Heather A.
    LEUKEMIA RESEARCH, 2007, 31 : S7 - S9
  • [37] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    BLOOD, 2008, 112 (11) : 1184 - 1184
  • [38] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1628 - 1629
  • [39] A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Raza, Azra
    Galili, Naomi
    Smith, Scott E.
    Godwin, John
    Boccia, Ralph V.
    Myint, Han
    Mahadevan, Daruka
    Mulford, Deborah
    Rarick, Mark
    Brown, Gail L.
    Schaar, Dale
    Faderl, Stefan
    Komrokji, Rami S.
    List, Alan F.
    Sekeres, Mikkael
    CANCER, 2012, 118 (08) : 2138 - 2147
  • [40] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, Maria
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Munoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez, Joaquin
    Merchan, Brayan
    del Canizo, Consuelo
    Vallespi, Teresa
    LANCET HAEMATOLOGY, 2015, 2 (06): : E260 - E266